These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16405225)

  • 1. Perspective and pharmacoeconomic analyses.
    Kozma CM
    Manag Care Interface; 2005 Dec; 18(12):53-4. PubMed ID: 16405225
    [No Abstract]   [Full Text] [Related]  

  • 2. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of clinical and economic evidence in dossier formulary submissions.
    Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
    Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic evaluations of antifungal therapies.
    Hennen CR
    Curr Med Res Opin; 2009 Jul; 25(7):1751-8. PubMed ID: 19557894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacoeconomics of acne treatment: where are we heading?
    Inglese MJ; Fleischer AB; Feldman SR; Balkrishnan R
    J Dermatolog Treat; 2008; 19(1):27-37. PubMed ID: 18273722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics: historical perspective.
    Bootman JL; McGhan WF; Townsend RJ
    Ann Pharmacother; 2006 Mar; 40(3):518-9. PubMed ID: 16478813
    [No Abstract]   [Full Text] [Related]  

  • 8. [National economic consequences of vaccines].
    Bergman A; Persson U
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1680-4. PubMed ID: 18590011
    [No Abstract]   [Full Text] [Related]  

  • 9. Current efforts in standards development. United States.
    Power EJ
    Med Care; 1996 Dec; 34(12 Suppl):DS200-3; discussion DS204-7. PubMed ID: 8969327
    [No Abstract]   [Full Text] [Related]  

  • 10. [Methodology of pharmacoeconomic studies in oncology].
    Ballatori E
    Recenti Prog Med; 2008 Jan; 99(1):42-7. PubMed ID: 18389873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulating vaccines: can health-economics tools be used profitably?
    Dhanasiri SK; Puliyel JM
    Indian Pediatr; 2007 Jan; 44(1):11-4. PubMed ID: 17277425
    [No Abstract]   [Full Text] [Related]  

  • 12. Now is the time for pharmacy performance incentives.
    Kaye T
    Manag Care; 2008 Jan; 17(1):32-3, 36. PubMed ID: 18274312
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceuticals and medicare managed care: pharmacoeconomic considerations.
    Cox ER; Coons SJ
    Clin Ther; 1998; 20(6):1238-40. PubMed ID: 9916615
    [No Abstract]   [Full Text] [Related]  

  • 14. Managed care considerations.
    Dunn JD
    Am J Manag Care; 2008 Jun; 14(6 Suppl 2):S227-37. PubMed ID: 18611104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managed care executives see utility in economic modeling for specialty injectables.
    Manag Care Interface; 2005; Suppl():12-3. PubMed ID: 16268199
    [No Abstract]   [Full Text] [Related]  

  • 16. The need for pharmacoeconomic studies of pharmacy services.
    Rascati KL; Moczygemba LR
    Clin Ther; 2007 Jul; 29(7):1488-90. PubMed ID: 17825700
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacoeconomic analyses--chance or 4th hurdle for innovative drugs].
    Krammer H
    Wien Med Wochenschr; 2006 Dec; 156(23-24):606-11. PubMed ID: 17211764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States.
    Rupnow MF; Chang AH; Shachter RD; Owens DK; Parsonnet J
    J Infect Dis; 2009 Oct; 200(8):1311-7. PubMed ID: 19751153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus guidelines for specialty pharmaceuticals: a best-practice approach for cost-effective management.
    Sullivan SD
    Am J Manag Care; 2004 Aug; 10(8 Suppl):S242-4; discussion 245-51. PubMed ID: 15460521
    [No Abstract]   [Full Text] [Related]  

  • 20. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.